Skip to main navigation SEC Filings Group Filing year - Any - Items per page 10 FILING DATE DESCRIPTION FORM FILING GROUP VIEW Nov 18, 2021 Report of unscheduled material events or corporate event 8-K Current Reports 0000950170-21-004738.pdf 0000950170-21-004738.rtf 0000950170-21-004738.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML Nov 18, 2021 Initial filing by director officer or owner of more than ten percent. 3 3,4,5 0001209191-21-065532.pdf 0001209191-21-065532.rtf 0001209191-21-065532.xls View HTML Nov 18, 2021 Statement of changes in beneficial ownership of securities 4 3,4,5 0001209191-21-065539.pdf 0001209191-21-065539.rtf 0001209191-21-065539.xls View HTML Nov 08, 2021 Report of unscheduled material events or corporate event 8-K Current Reports 0001104659-21-135227.pdf 0001104659-21-135227.rtf 0001104659-21-135227.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML Nov 05, 2021 Quarterly report which provides a continuing view of a company's financial position 10-Q Quarterly Filings 0000950170-21-003247.pdf 0000950170-21-003247.rtf 0000950170-21-003247.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML Oct 05, 2021 Official notification to shareholders of matters to be brought to a vote ("Proxy") DEF 14A Proxy Filings 0001564590-21-050089.pdf 0001564590-21-050089.rtf 0001564590-21-050089.xls View HTML Sep 30, 2021 Report of unscheduled material events or corporate event 8-K Current Reports 0001104659-21-121022.pdf 0001104659-21-121022.rtf 0001104659-21-121022.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML Sep 29, 2021 Statement of changes in beneficial ownership of securities 4 3,4,5 0001209191-21-058036.pdf 0001209191-21-058036.rtf 0001209191-21-058036.xls View HTML Sep 28, 2021 Statement of changes in beneficial ownership of securities 4 3,4,5 0001209191-21-057957.pdf 0001209191-21-057957.rtf 0001209191-21-057957.xls View HTML Sep 22, 2021 A preliminary proxy statement providing notification matters to be brought to a vote PRE 14A Proxy Filings 0001564590-21-048586.pdf 0001564590-21-048586.rtf 0001564590-21-048586.xls View HTML Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Displaying 1 - 10 of 1023 results Data provided by Kaleidoscope. Tools PRINT EMAIL ALERTS RSS FEEDS EMAIL PAGE © 2021 Sorrento Therapeutics. All Rights Reserved. Footer Terms of Use Privacy Policy DMCA Trademarks Linking Policy

HISTORY Our Accomplishments: Sorrento has had a long journey from a humble beginning to a diversified biopharma discovering and developing life changing medicine. 2009 Founded 2013 Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc. Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp. © 2021 Sorrento Therapeutics, Inc. All Rights Reserved. Terms of Use | Forward Looking Statements | Privacy Policy | Cookie Policy | Notices